Identification | Back Directory | [Name]
CAY10683 (SantacruzaMate A) | [CAS]
1477949-42-0 | [Synonyms]
CAY1083 CS-1702 CAY10683 SantacruzaMate A 8-Trihydroxyflavone CAY 10683;CAY-10683 Santacruzamate A, >98% Santacruzamate A (CAY10683) CAY10683 (SantacruzaMate A) ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE N-[4-oxo-4-[(2-phenylethyl)amino]butyl]-carbamic acid ethyl ester Carbamic acid, N-[4-oxo-4-[(2-phenylethyl)amino]butyl]-, ethyl ester | [Molecular Formula]
C15H22N2O3 | [MDL Number]
MFCD28348356 | [MOL File]
1477949-42-0.mol | [Molecular Weight]
278.35 |
Chemical Properties | Back Directory | [Boiling point ]
508.1±43.0 °C(Predicted) | [density ]
1.087±0.06 g/cm3(Predicted) | [storage temp. ]
-20° | [solubility ]
Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 20 mg/ml). | [form ]
solid | [pka]
12.68±0.46(Predicted) | [color ]
Off-white | [Stability:]
Stable for 2 years from date of purchse as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. |
Hazard Information | Back Directory | [Description]
Santacruzamate A (1477949-42-0) is a highly potent and selective inhibitor of HDAC2 isolated from the Panamanian marine cyanobacterium?cf. Symploca?(IC50=0.119 and 434 nM for HDAC2 and HDAC6 respectively).1?Induces apoptosis and cancer cell death only in combination with other HDAC1 inhibitors.2?Potential therapeutic agent for breast cancer.3?Attenuates Aβ fragment (Aβ25-35)-induced toxicity in PC12 cells by enhancing ER stress tolerance.4?Ameliorates Alzheimer’s disease-like pathology in mouse models.4 | [Uses]
Santacruzamate A is a natural product isolated from Panamanian marine cyanobacterium Symploca sp; a histone deacetylases (HDACs) inhibitor; an attractive targeted therapy against breast cancer in women. | [Definition]
ChEBI: Santacruzamate A is an organooxygen compound and an organonitrogen compound. It is functionally related to a gamma-amino acid. | [storage]
Store at -20°C | [References]
1) Pavlik?et al.?(2013),?Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; J. Nat. Prod.,?76?2026
2) Zhou?et al.?(2018),?Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma; Cell Prolif.,?51(3)?e12447
3) Damaskos?et al.?(2017),?Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer;?Anticancer Res.,?37?35
4) Chen?et al.?(2019),?Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR in vivo and in vitro;?Front. Cell. Neurosci.,?13?61 |
|
|